BioSpace News Archive

NRGene announced today some notable changes to its executive leadership team, taking effect as the company expands its global footprint and opens a new office in San Diego, California

Physicians’ Education Resource® (PER®), a leading resource for continuing medical education (CME), will conduct two CME-accredited satellite symposia on bladder cancer and renal cell carcinoma at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium on Feb. 14 and 15 at the San Francisco Marriott Marquis in California, announced Phil Talamo, president of PER®.

Catalent, Inc. (NYSE: CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the second quarter of fiscal year 2019 ended December 31, 2018, before the market open on Tuesday, February 5, 2019.

Patterson Companies (Nasdaq: PDCO) announced that Eric Shirley will join Patterson as President of the Dental business unit effective February 4, 2019.

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (“low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX:NVCN) announced today that it has received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market.

MG Labs Provides Consistent, Quality Products to a New Health Market

Quadax Inc. will present strategies for laboratories to improve collections and reduce administrative burden at the 14th Semi-Annual Q1 Diagnostic Coverage & Reimbursement Conference West

Data will be presented at ASCO 2019 Gastrointestinal Cancers Symposium

BCG’s Analysis of Hepatitis C Cures Reveals That a Payer Licensing Agreement Is More Advantageous--For Patients, Payers, and Pharmaceutical Companies--Than the Current Approach